47 studies found for:    "Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Show Display Options
RSS Create an RSS feed from your search for:
"Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Skeletal Disorders and Short Stature
Conditions: Developmental Bone Disease;   Dwarfism;   Skeletal Dysplasias
2 Recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific T cells
3 Completed Angiotensin II Antagonism of TGF-Beta 1
Conditions: Diabetic Nephropathy;   Hypertension
Intervention: Drug: Candesartan
4 Active, not recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
5 Completed Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers
Condition: Healthy
Interventions: Drug: P144 cream;   Drug: Placebo
6 Recruiting Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects
Condition: Hypertension
7 Completed Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Conditions: Pancreatic Neoplasms;   Melanoma;   Colorectal Neoplasms
Intervention: Drug: AP 12009
8 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
9 Not yet recruiting Study of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: LY2157299
10 Active, not recruiting Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)
Conditions: Lymphoma;   Hodgkin's Disease;   Relapse;   Lymphoma, Non-Hodgkin
Intervention: Genetic: TGFbeta resistant LMP-specific CTLs
11 Completed Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
Condition: Asthma
Intervention: Drug: montelukast
12 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
13 Recruiting TGF-(Beta) and Susceptibility to RSV
Conditions: Respiratory Syncytial Virus;   Asthma
14 Terminated
Has Results
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
15 Withdrawn Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome
Condition: Marfan Syndrome
Intervention: Other: Blood draw
16 Completed Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Lung Cancer;   Prostate Cancer
Interventions: Procedure: venipuncture;   Radiation: radiation therapy
17 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
18 Completed Radiation Therapy in Treating Women With Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Radiation: radiation therapy
19 Completed Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Conditions: Lung Neoplasm;   Carcinoma, Bronchogenic
Intervention: Biological: Lucanix
20 Recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years